Pancreatic cancer therapy Phase 2 underway


OncoMed Pharmaceuticals (NASDAQ:OMED) commences patient dosing in its randomized placebo-controlled 124-patient Phase 2 clinical trial evaluating the safety and efficacy of OMP-59R5 (tarextumab) in patients with pancreatic cancer. Tarextumab is being tested in combination with Abraxane (paclitaxel) plus gemcitabine in patients with previously untreated stage IV pancreatic cancer. The primary endpoint is progression-free survival (PFS) compared to placebo.

The one-year survival rate for newly diagnosed patients is only 20%.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs